https://www.onclive.com/view/peak-sets-the-stage-for-bezuclastinib-sunitinib-to-move-into-the-advanced-gist-treatment-paradigm2026-08-21T21:45:00Z2026-08-21T21:45:00Z https://www.onclive.com/view/frequently-asked-questions-on-first-line-metastatic-tnbc-management2026-08-21T19:36:29.641Z2026-08-21T19:36:29.641Z https://www.onclive.com/view/dr-pelster-on-the-rationale-for-investigating-atebimetinib-in-metastatic-pancreatic-cancer2026-08-21T19:30:00Z2026-08-21T19:30:00Z https://www.onclive.com/view/dr-wainberg-on-incb161734-activity-in-refractory-pancreatic-cancer2026-08-21T19:10:00Z2026-08-21T19:10:00Z https://www.onclive.com/view/treatment-goals-and-frontline-strategies-in-multiple-myeloma2026-08-21T18:10:00Z2026-08-21T18:10:00Z https://www.onclive.com/view/evolving-treatment-goals-in-multiple-myeloma2026-08-21T18:05:35.040Z2026-08-21T18:05:35.040Z https://www.onclive.com/view/precision-immunotherapy-pet-adapted-regimens-and-novel-targets-are-redefining-hodgkin-lymphoma-care-with-chandler-park-md-joshua-brody-md2026-08-21T17:07:39.485Z2026-08-21T17:07:39.485Z https://www.onclive.com/view/lymphoma-s-revolution-evens-rhodes-on-cll-car-t-and-nj-care2026-08-21T17:00:00Z2026-08-21T17:00:00Z https://www.onclive.com/view/china-s-nmpa-accepts-nda-for-opamtistomig-in-pretreated-advanced-extrapulmonary-nec2026-08-21T16:56:13.911Z2026-08-21T16:56:13.911Z https://www.onclive.com/view/obesity-weakens-anti-tumor-immune-response-in-lung-cancer-but-exercise-may-restore-it2026-08-21T16:00:00Z2026-08-21T16:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-8-21-2026-lung-bladder-endometrial-cancer-updates2026-08-21T13:00:00Z2026-08-21T13:00:00Z https://www.onclive.com/view/european-commission-approves-teclistamab-plus-daratumumab-for-r-r-myeloma2026-08-21T12:41:35.570Z2026-08-21T12:41:35.570Z https://www.onclive.com/view/the-2025-nccn-guideline-update-for-ca-lems-in-small-cell-lung-cancer-what-changed-and-what-still-needs-to-change-plus-cancer-directed-treatment-as-primary-intervention2026-08-21T12:05:00Z2026-08-21T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-bridging-therapy-before-car-t-cell-therapy2026-08-21T12:05:00Z2026-08-21T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-optimizing-early-referral-and-care-coordination2026-08-21T12:00:00Z2026-08-21T12:00:00Z https://www.onclive.com/view/asco-issues-first-guideline-on-ctdna-testing-in-solid-tumors-and-lymphoma2026-08-21T12:00:00Z2026-08-21T12:00:00Z https://www.onclive.com/view/integrating-discordant-results-in-ca-lems-workup-who-reconciles-the-data-and-why-the-oncologist-must-stay-in-the-loop2026-08-21T12:00:00Z2026-08-21T12:00:00Z https://www.onclive.com/view/pancreatic-cancer-treatment-advances-call-for-a-renewed-focus-on-the-role-of-liposomal-irinotecan-with-jennifer-b-valerin-md-phd2026-08-20T21:25:00Z2026-08-20T21:25:00Z https://www.onclive.com/view/asco-guideline-update-broadens-first-line-treatment-options-for-her2-gastroesophageal-cancer2026-08-20T20:30:00Z2026-08-20T20:30:00Z https://www.onclive.com/view/ptvg-hp-dna-vaccine-extends-overall-survival-vs-placebo-in-psa-recurrent-prostate-cancer2026-08-20T17:16:28.799Z2026-08-20T17:16:28.799Z https://www.onclive.com/view/fda-awards-fast-track-designation-to-safusidenib-in-idh1-mutant-glioma2026-08-20T16:29:34.877Z2026-08-20T16:29:34.877Z https://www.onclive.com/view/fda-approves-first-celmod-agent-with-dana-farber-helping-advance-its-development2026-08-20T16:00:00Z2026-08-20T16:00:00Z https://www.onclive.com/view/car-t-cell-therapy-continues-to-make-its-case-in-early-relapsed-myeloma2026-08-20T15:55:00Z2026-08-20T15:55:00Z https://www.onclive.com/view/fda-grants-breakthrough-therapy-and-fast-track-status-to-68ga-nym096-in-ccrcc2026-08-20T14:14:10.323Z2026-08-20T14:14:10.323Z https://www.onclive.com/view/enzalutamide-plus-talazoparib-shows-activity-in-mhspc2026-08-20T13:00:00Z2026-08-20T13:00:00Z https://www.onclive.com/view/mechanistic-differences-between-pd-1-and-pd-l1-blockade2026-08-20T12:05:00Z2026-08-20T12:05:00Z https://www.onclive.com/view/monitoring-treatment-response-in-egfr-mutant-nsclc2026-08-20T12:05:00Z2026-08-20T12:05:00Z https://www.onclive.com/view/managing-treatment-related-toxicities-in-egfr-mutant-nsclc2026-08-20T12:00:00Z2026-08-20T12:00:00Z https://www.onclive.com/view/real-world-experience-and-integrating-flaura2-top-and-flame-into-practice2026-08-20T12:00:00Z2026-08-20T12:00:00Z https://www.onclive.com/view/interpreting-keynote-630-in-the-context-of-c-post2026-08-20T12:00:00Z2026-08-20T12:00:00Z https://www.onclive.com/view/dr-oberstein-on-the-design-of-autogene-cevumeran-in-pdac2026-08-19T19:36:27.756Z2026-08-19T19:36:27.756Z https://www.onclive.com/view/dr-morillo-on-the-safety-profile-of-golcadomide-in-r-r-follicular-lymphoma2026-08-19T19:30:00Z2026-08-19T19:30:00Z https://www.onclive.com/view/symptom-impact-and-patient-discussion-anchor-treatment-decision-making-in-systemic-mastocytosis2026-08-19T18:41:23.402Z2026-08-19T18:41:23.402Z https://www.onclive.com/view/dr-morillo-on-efficacy-data-for-golcadomide-in-r-r-follicular-lymphoma2026-08-19T18:06:27.130Z2026-08-19T18:06:27.130Z https://www.onclive.com/view/dr-cort-s-on-developing-cd47-as-a-biomarker-in-pretreated-her2-breast-cancer2026-08-19T17:30:00Z2026-08-19T17:30:00Z https://www.onclive.com/view/mrna-vaccines-may-help-increase-long-term-disease-control-in-pdac2026-08-19T17:00:00Z2026-08-19T17:00:00Z https://www.onclive.com/view/dr-skoulidis-on-first-line-divarasib-plus-pembrolizumab-in-kras-g12c-nsclc2026-08-19T16:00:00Z2026-08-19T16:00:00Z https://www.onclive.com/view/biomarkers-may-help-identify-patients-with-lung-cancer-who-benefit-most-from-perioperative-immunotherapy2026-08-19T16:00:00Z2026-08-19T16:00:00Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-pln-101095-plus-pembrolizumab-in-solid-tumors2026-08-19T15:48:56.163Z2026-08-19T15:48:56.163Z https://www.onclive.com/view/esmo-guidelines-express-update-recommends-daraxonrasib-for-ras-g12-mutated-metastatic-pdac2026-08-19T14:35:00Z2026-08-19T14:35:00Z https://www.onclive.com/view/harold-p-freeman-md-pioneer-of-patient-navigation-and-cancer-disparities-research-dies-at-932026-08-19T14:22:04.920Z2026-08-19T14:22:04.920Z https://www.onclive.com/view/intismeran-autogene-plus-pembrolizumab-meets-rfs-dmfs-end-points-in-resected-melanoma2026-08-19T12:10:00Z2026-08-19T12:10:00Z https://www.onclive.com/view/mo-rez-advances-into-combination-studies-following-robust-responses-in-gynecologic-cancers2026-08-19T12:06:20.276Z2026-08-19T12:06:20.276Z https://www.onclive.com/view/breast-cancer-endocrine-therapy-profiles-prompt-individualized-toxicity-management-conversations-with-sara-nunnery-md-msci-and-eleonora-teplinsky-md2026-08-18T20:55:00Z2026-08-18T20:55:00Z https://www.onclive.com/view/updated-serena-6-data-sharpen-the-debate-on-early-ctdna-guided-switching-in-advanced-breast-cancer2026-08-18T19:34:31.817Z2026-08-18T19:34:31.817Z https://www.onclive.com/view/for-early-prostate-cancer-active-surveillance-is-now-1-choice2026-08-18T16:00:00Z2026-08-18T16:00:00Z https://www.onclive.com/view/dr-garg-on-the-safety-profile-of-proton-therapy-in-head-and-neck-cancer2026-08-18T15:08:18.329Z2026-08-18T15:08:18.329Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-bh-30643-in-egfr-c797s-nsclc2026-08-18T14:45:00Z2026-08-18T14:45:00Z https://www.onclive.com/view/dr-hurvitz-on-serena-6-and-weighing-an-early-switch-to-camizestrant-in-breast-cancer2026-08-18T14:30:00Z2026-08-18T14:30:00Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-etx-19477-in-brca-mutated-hr-her2-breast-cancer2026-08-18T14:24:32.421Z2026-08-18T14:24:32.421Z https://www.onclive.com/view/posttransplant-dordaviprone-maintenance-safe-low-cytopenia-high-risk-aml-mds2026-08-18T13:00:00Z2026-08-18T13:00:00Z https://www.onclive.com/view/hypersensitivity-silent-inactivation-and-premedication-strategies-for-pegaspargase-in-aya-all2026-08-18T12:05:00Z2026-08-18T12:05:00Z https://www.onclive.com/view/nma-associates-mrd-negative-cr-with-pfs-in-earlier-line-r-r-myeloma2026-08-18T12:00:00Z2026-08-18T12:00:00Z https://www.onclive.com/view/therapeutic-drug-monitoring-and-dose-optimization-of-pegaspargase-in-aya-all2026-08-18T12:00:00Z2026-08-18T12:00:00Z https://www.onclive.com/view/dr-viansone-on-the-future-of-her2-metastatic-breast-cancer-management2026-08-17T22:35:00Z2026-08-17T22:35:00Z https://www.onclive.com/view/key-considerations-for-health-equity-and-patient-centered-care-in-tnbc2026-08-17T21:07:06.422Z2026-08-17T21:07:06.422Z https://www.onclive.com/view/dr-morillo-on-the-mechanism-of-action-for-golcadomide-in-r-r-follicular-lymphoma2026-08-17T19:15:07.993Z2026-08-17T19:15:07.993Z https://www.onclive.com/view/dr-leary-on-a-neo-epitope-based-vaccine-with-or-without-pembrolizumab-in-platinum-sensitive-recurrent-ovarian-cancer2026-08-17T17:45:00Z2026-08-17T17:45:00Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-sapanisertib-and-serabelisib-plus-paclitaxel-in-advanced-endometrial-cancer2026-08-17T16:05:00Z2026-08-17T16:05:00Z https://www.onclive.com/view/developing-tomorrow-s-cancer-treatments-today-meet-a-pediatric-oncologist-working-to-save-kids-with-leukemia2026-08-17T16:00:00Z2026-08-17T16:00:00Z https://www.onclive.com/view/dr-viansone-on-adc-sequencing-in-metastatic-her2-breast-cancer2026-08-17T14:30:00Z2026-08-17T14:30:00Z https://www.onclive.com/view/osimertinib-plus-savolitinib-improves-pfs-and-os-in-pretreated-met-egfr-nsclc2026-08-17T14:30:00Z2026-08-17T14:30:00Z https://www.onclive.com/view/t-dxd-improves-pfs-in-first-line-her2-mutant-nsclc2026-08-17T14:16:55.368Z2026-08-17T14:16:55.368Z https://www.onclive.com/view/nda-is-submitted-for-ugn-103-for-recurrent-low-grade-intermediate-risk-nmibc2026-08-17T14:11:37.796Z2026-08-17T14:11:37.796Z https://www.onclive.com/view/evolve-lung02-trial-of-volrustomig-discontinued-in-first-line-metastatic-nsclc2026-08-17T13:40:00.702Z2026-08-17T13:40:00.702Z https://www.onclive.com/view/adding-sbrt-to-nivolumab-ipilimumab-fails-to-improve-outcomes-in-mcrpc2026-08-17T11:48:22.823Z2026-08-17T11:48:22.823Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-8-92026-08-16T10:00:00Z2026-08-16T10:00:00Z https://www.onclive.com/view/dive-into-the-data-supporting-the-fda-approval-of-iberdomide-plus-daratumumab-dexamethasone-in-r-r-myeloma2026-08-16T10:00:00Z2026-08-16T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-8-92026-08-15T12:00:00Z2026-08-15T12:00:00Z https://www.onclive.com/view/dr-viansone-on-balancing-adcs-and-low-toxicity-chemotherapy-in-her2-breast-cancer2026-08-15T00:40:00Z2026-08-15T00:40:00Z https://www.onclive.com/view/novel-approaches-for-hematocrit-control-are-driving-research-in-polycythemia-vera2026-08-14T18:38:37.795Z2026-08-14T18:38:37.795Z https://www.onclive.com/view/dr-morris-on-notable-ongoing-research-in-prostate-cancer2026-08-14T18:27:18.686Z2026-08-14T18:27:18.686Z https://www.onclive.com/view/dr-viansone-on-de-escalating-chemotherapy-type-and-duration-in-her2-positive-breast-cancer2026-08-14T17:30:00Z2026-08-14T17:30:00Z https://www.onclive.com/view/pembrolizumab-plus-denosumab-yields-responses-pretreated-advanced-clear-cell-rcc2026-08-14T17:00:00Z2026-08-14T17:00:00Z https://www.onclive.com/view/dr-bhatia-on-adjuvant-avelumab-in-patients-with-merkel-cell-carcinoma-and-lymph-node-metastases2026-08-14T16:50:00Z2026-08-14T16:50:00Z https://www.onclive.com/view/new-study-suggests-genomic-newborn-screening-could-identify-some-children-at-risk-for-early-cancers2026-08-14T16:00:00Z2026-08-14T16:00:00Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-spevatamig-in-advanced-and-metastatic-biliary-tract-carcinoma2026-08-14T15:20:00Z2026-08-14T15:20:00Z https://www.onclive.com/view/fda-approval-insights-gedatolisib-plus-fulvestrant-palbociclib-for-hr-her2-negative-pik3ca-wild-type-advanced-breast-cancer-with-adam-m-brufsky-md-phd2026-08-14T14:30:00Z2026-08-14T14:30:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-8-14-2026-did-you-catch-this-week-s-myeloma-lung-cancer-and-polycythemia-vera-updates-2026-08-14T14:00:00Z2026-08-14T14:00:00Z https://www.onclive.com/view/longer-term-data-continue-to-support-earlier-integration-of-car-t-cell-therapy-in-r-r-myeloma2026-08-14T13:00:00Z2026-08-14T13:00:00Z https://www.onclive.com/view/distinguishing-ca-lems-from-myasthenia-gravis-ici-toxicities-and-chemotherapy-related-weakness-in-small-cell-lung-cancer2026-08-14T12:05:00Z2026-08-14T12:05:00Z https://www.onclive.com/view/seronegative-ca-lems-in-small-cell-lung-cancer-next-steps-and-the-role-of-electrodiagnostic-testing2026-08-14T12:00:00Z2026-08-14T12:00:00Z https://www.onclive.com/view/trastuzumab-rezetecan-elicits-high-orr-in-her2-high-and-her2-low-salivary-gland-carcinoma2026-08-14T12:00:00Z2026-08-14T12:00:00Z https://www.onclive.com/view/dr-carlino-on-5-year-data-with-intismeran-plus-pembrolizumab-in-resected-melanoma2026-08-13T22:40:00Z2026-08-13T22:40:00Z https://www.onclive.com/view/dr-rodriguez-on-the-rationale-for-testing-lag-3-pd-1-dual-blockade-in-nonsquamous-nsclc2026-08-13T22:35:00Z2026-08-13T22:35:00Z https://www.onclive.com/view/dr-banerjee-on-the-fda-approval-of-iberdomide-plus-daratumumab-dexamethasone-in-r-r-myeloma2026-08-13T21:00:48.969Z2026-08-13T21:00:48.969Z https://www.onclive.com/view/dr-garg-on-a-phase-3-study-of-proton-therapy-in-head-and-neck-cancer2026-08-13T20:21:19.955Z2026-08-13T20:21:19.955Z https://www.onclive.com/view/fda-approves-iberdomide-plus-daratumumab-dexamethasone-for-r-r-myeloma2026-08-13T20:13:21.655Z2026-08-13T20:13:21.655Z https://www.onclive.com/view/frequently-asked-questions-on-the-evolving-management-of-early-stage-her2-breast-cancer2026-08-13T17:46:42.925Z2026-08-13T17:46:42.925Z https://www.onclive.com/view/study-finds-traditional-prostate-cancer-risk-factors-do-not-predict-hormone-therapy-benefit2026-08-13T16:00:00Z2026-08-13T16:00:00Z https://www.onclive.com/view/dr-morris-on-updated-data-with-lutetium-lu-177-vipivotide-tetraxetan-plus-an-arpi-in-psma-mhspc2026-08-13T15:55:21.430Z2026-08-13T15:55:21.430Z https://www.onclive.com/view/zipalertinib-plus-chemotherapy-improves-pfs-in-first-line-egfr-exon-20-insertion-nsclc2026-08-13T14:30:00Z2026-08-13T14:30:00Z https://www.onclive.com/view/pooled-analysis-reveals-strong-pirtobrutinib-efficacy-in-frontline-cll2026-08-13T14:00:00Z2026-08-13T14:00:00Z https://www.onclive.com/view/lutetium-lu-177-vipivotide-tetraxetan-approval-reshapes-the-treatment-landscape-for-psma-mhspc2026-08-13T13:00:00Z2026-08-13T13:00:00Z https://www.onclive.com/view/re-biopsy-practices-and-closing-takeaways2026-08-13T12:15:00Z2026-08-13T12:15:00Z https://www.onclive.com/view/subcutaneous-amivantamab-in-egfr-mutant-nsclc2026-08-13T12:05:00Z2026-08-13T12:05:00Z https://www.onclive.com/view/identifying-patients-with-high-risk-disease2026-08-13T12:05:00Z2026-08-13T12:05:00Z https://www.onclive.com/view/second-line-nccn-options-and-approach-to-progression2026-08-13T12:00:00Z2026-08-13T12:00:00Z https://www.onclive.com/view/flame-data-and-the-role-of-ctdna2026-08-13T12:00:00Z2026-08-13T12:00:00Z https://www.onclive.com/view/comparing-osimertinib-based-frontline-combination-regimens-in-egfr-mutant-nsclc2026-08-13T12:00:00Z2026-08-13T12:00:00Z